Ospemifene: A safe treatment of vaginal atrophy

L. Del Pup

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: Vaginal atrophy is a chronic, progressive medical condition that affects fifty percent of postmenopausal women, causing symptoms like dyspareunia, vaginal dryness, and vaginal irritation. Until recently, the only prescription options were systemic and vaginal estrogen therapies that might be limited by concerns about long-Term safety and breast cancer risk. The objective is to analyze the literature about ospemifene, a tissue-selective estrogen receptor modulator (SERM) recently approved for the treatment of vulvovaginal atrophy and dyspareunia and to compare its effects with those of the other SERMs to assess its safety. MATERIALS AND METHODS: Review. Medline search. RESULTS: Ospemifene treats vaginal atrophy, and, if compared with other SERMS, it has no or not significant effects on endometrium and thromboembolism. Experimental and animal models suggest an inhibitory effect on the growth of malignant breast tissue. The available clinical data support ospemifene breast safety. CONCLUSIONS: Ospemifene relieves moderate to severe symptoms of vulvovaginal atrophy, like dryness, irritation and soreness around the genital area, and painful sexual intercourse, in menopausal women. It is well tolerated, and it has neutral effects on endometrium and coagulation. Clinical trials and even long-Term studies on breast cancer effects support ospemifene overall safety.

Original languageEnglish
Pages (from-to)3934-3944
Number of pages11
JournalEuropean Review for Medical and Pharmacological Sciences
Volume20
Issue number18
Publication statusPublished - 2016

Keywords

  • Bazedoxifene
  • Bone density
  • Breast cancer
  • Endometrial cancer
  • Ospemifene
  • Raloxifene
  • Serm
  • Tamoxifen
  • Thromboembolism
  • Vaginal atrophy

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Ospemifene: A safe treatment of vaginal atrophy'. Together they form a unique fingerprint.

Cite this